Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype
This trial is active, not recruiting.
|Condition||coronary heart disease|
|Sponsor||Cardiovascular Institute & Fuwai Hospital|
|Start date||October 2012|
|End date||November 2013|
|Trial size||880 participants|
|Trial identifier||NCT01710436, RDPAC2012|
This study is a prospective, observational study to estimate the relationship between dosage of clopidogrel and platelet aggregation in Chinese with different genotype. The investigators suppose both pretreatment dosage of clopidogrel before percutaneous coronary intervention (PCI) and CYP2C19 genotype may effect the platelet aggregation as well as clinical outcome.
|Observational model||case control|
Change from Baseline in platelet aggregation
time frame: 1 month and 6 months after PCI
Major adverse cardiovascular events (MACE); Bleeding events
time frame: 6 months after PCI
Male or female participants at least 18 years old.
- accept PCI in Chinese CHD patients
- expected dual antiplatelet therapy (DAPT) at least 6 months
- another planned PCI within 6 months
Call for more information